ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Sells $40,132.56 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark C. Schneyer sold 2,708 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total transaction of $40,132.56. Following the sale, the executive vice president now owns 59,456 shares of the company’s stock, valued at approximately $881,137.92. The trade was a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

ACADIA Pharmaceuticals Trading Down 3.5 %

NASDAQ:ACAD traded down $0.51 during trading hours on Tuesday, reaching $14.10. 1,982,762 shares of the company were exchanged, compared to its average volume of 1,841,010. The firm has a market cap of $2.35 billion, a PE ratio of 18.08 and a beta of 0.54. ACADIA Pharmaceuticals Inc. has a twelve month low of $13.89 and a twelve month high of $20.68. The stock’s 50-day moving average is $17.89 and its 200-day moving average is $17.00.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ACAD. Summit Investment Advisors Inc. boosted its holdings in ACADIA Pharmaceuticals by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 12,519 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 795 shares during the last quarter. Arete Wealth Advisors LLC lifted its position in shares of ACADIA Pharmaceuticals by 15.9% in the fourth quarter. Arete Wealth Advisors LLC now owns 13,700 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 1,875 shares in the last quarter. KBC Group NV boosted its stake in shares of ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 2,044 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth approximately $39,000. Finally, R Squared Ltd acquired a new position in ACADIA Pharmaceuticals in the 4th quarter valued at $47,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price for the company. StockNews.com upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $23.00 to $20.00 in a report on Friday, January 3rd. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $23.93.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.